Perspective Therapeutics unit enters Cesium-131 supply deal with Russian state firm through March 2025

Perspective Therapeutics, Inc.

Isoray Medical signed contract with JSC Isotope for Cesium-131; supersedes November 2022 agreement.
Contract effective January 1, 2024 through March 31, 2025; price and volume redacted as confidential.
Buyer agrees Russian sanctions do not excuse performance; dispute resolution under Hong Kong law/HKIAC.
Payment due 30 calendar days after delivery in USD via intermediary bank; shipping FCA Russia.
Goods restricted to medical source production; no military use; seller may inspect end-use compliance.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Perspective Therapeutics, Inc. entered into 2024 Agreement with Joint Stock Company «Isotope» (effective 2023-12-05).

Action: entry
Agreement: supply
Counterparty: Joint Stock Company «Isotope»
Effective: 2023-12-05

Exact text from the filing

On December 5, 2023, Isoray Medical, Inc. (“Medical”), a wholly-owned subsidiary of Perspective Therapeutics, Inc. (the “Company”), entered into a supply contract (the “2024 Agreement”) with Joint Stock Company «Isotope», a Russian company (“JSC Isotope”).

View on SEC.gov

230 material agreements filed in the last 30 days. Browse all material agreements →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-033769

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.